M. D. Anderson
Patients and Public Cancer Professionals About M. D. Anderson Site Map Contact Us Search
  Printer Friendly Page

ovarian cancer

Ovarian Cancer Basics

Each year, about 22,000 women in the United States are diagnosed with ovarian cancer. The symptoms of ovarian cancer are often common and vague, which makes it difficult to diagnose.

There are more than 30 different types of ovarian tumors, which are categorized according to the cell type. Some are benign (noncancerous) and do not spread beyond the ovary. Malignant (cancerous) tumors can spread to other parts of the body.

Currently, there is no effective early detection method for ovarian cancer. It is usually diagnosed in advanced stages, and only about half of women survive longer than five years after diagnosis. For the 25% of ovarian cancers that are found early, the five-year survival is greater than 90%.

Studies have shown that prognosis and survival depend largely on how much tumor is left at the time of initial surgery. Patients who have no remaining tumor or with only nodules less than one centimeter in diameter have the best chance for cure and long-term survival.

Ovarian Cancer Treatment at M. D. Anderson

Request an Appointment
Submit our
Online Self-Referral Form or call 1-877-MDA-6789.

Clinical Trials
Learn about our open ovarian cancer clinical trials by searching our online database.

Patient Power: Advances in the Treatment of Ovarian Cancer (38:36)
New advances in drug development and surgical techniques for ovarian cancer are discussed. (August 2007)
Download  /  Listen  /  Transcript (pdf)

Ovarian cancer patients are treated in our Gynecologic Oncology Center.

Ovarian Cancer Risk, Prevention, Screening & Early Detection

Prevention, Screening & Early Detection

Genetic Risk Assessment

Ovarian Cancer Education & Support


Patient Power: Personalized Medicine for Breast & Ovarian Cancer (59:55)
Studies show that patients with the same type of cancer can have very different outcomes, even with the same treatment. Learn how physicians and researchers are developing personalized medicine treatment plans for each patient based on the molecular markers of their tumor. (June 2008)
Download  / 
Listen

Patient Stories

Survivor Support

Ovarian Cancer Research
The Blanton-Davis Ovarian Cancer Research Program was created in 1996 to develop accurate screening methods and, ultimately, a cure for ovarian cancer. Its mission is threefold: innovative research for diagnosis, prevention and treatment; establishing public education initiatives; and raising public awareness about ovarian cancer.

Related Sites

Sprint for Life 5K Run & Walk
Sprint for Life Graphic
This annual event attracts more than 1,500 runners of all ages and abilities, who help raise funds for ovarian cancer research. For more information, visit the Sprint for Life website.

News & Articles

Blocking TG2 in Mice Reduces Ovarian Cancer

Ovarian Cancer Patients Need BRCA1/2 Facts

Rare Ovarian Cancer More Difficult to Treat

Cancer-Promoting Protein in Ovarian Cancer May Be Stopped with RNA Liposome

Researchers Identify and Shut Down Protein that Fuels Ovarian Cancer

Recognize the Signs of Ovarian Cancer

More...


Our monthly online cancer publication
Go to
this month's issue


How to Help Graphic
You may give to a specific type of research, program or event with our
Online Donation Form.

 

askMDAnderson about Cancer

A cancer diagnosis comes with many questions. askMDAnderson has answers.
1-877-MDA-6789
International patients call:
 (713) 745-0450

www.mdanderson.org/ask
En Español

Links & Resources

NOTE: Pages will open in a new browser window. M. D. Anderson does not endorse external sites.

American Cancer Society

National Cancer Institute

U.S. News Cancer Center: Ovarian Cancer

Conversations!

NCCN Patient Guidelines (Español)

More...

   

©2008 The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd, Houston, TX 77030
1-800-392-1611 (USA) / 1-713-792-6161   (5)

Legal Statements  |  Become a Patient  |  Make a Donation  |  Subscribe to Newsletters | RSS